8-K12B filed April 24, 2026, 7:59 PM ET ticker SNTI CIK 0001854270

other material confidence high sentiment neutral materiality 0.30

Senti Biosciences completes holding company reorganization; shares convert 1:1 to new parent SNTI

Senti Biosciences, Inc.

Senti Biosciences Holdings becomes new public parent; each share of old common stock converted 1:1 into new common stock.
Stock continues trading on Nasdaq under same ticker SNTI; new CUSIP 816944 102.
No change in executive officers or board of directors; same management team remains in place.
Reorganization is tax-free for shareholders; no vote required under DGCL Section 251(g).
Business, assets, and operations of the combined entity are unchanged from pre-reorganization.

item 1.01 item 3.01 item 3.03 item 5.01 item 5.02 item 5.03 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-177157
form_type: 8-K12B
ticker: SNTI
cik: 0001854270
company_name: Senti Biosciences, Inc.
filed_at: 2026-04-24T23:59:59+00:00
discovered_at: 2026-05-14T18:02:33.141232+00:00
generated_at: 2026-05-15T04:14:03.979585+00:00
sec_items: ["1.01", "3.01", "3.03", "5.01", "5.02", "5.03", "8.01", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-177157
json_url: https://secwatch.observer/filing/0001193125-26-177157.json
markdown_url: https://secwatch.observer/filing/0001193125-26-177157.md
text_url: https://secwatch.observer/filing/0001193125-26-177157.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1854270/000119312526177157/0001193125-26-177157-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1854270/000119312526177157/d279931d8k12b.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source-grounded claims

1d06f0dbb4c2f38f0ac3b299058001bd9a15f4e4

Senti Biosciences, Inc.: Upon consummation of the Reorganization, Senti Biosciences amended and restated its bylaws to simplify them after becoming a wholly-owned subsidiary (effective 2026-04-24).

Senti Biosciences also amended and restated its bylaws (as so amended and restated, the “Amended and Restated Senti Biosciences Bylaws”) in order to simplify its bylaws in light of Senti Biosciences having become a wholly-owned subsidiary of Senti Holdings, which is a wholly owned subsidiary of Senti Biosciences Holdings.

SEC 8-K Item 5.03/5.05/5.06 confidence 0.4 SEC evidence

280b1a9ee7a7c3931d1f6730542503b172187413

Senti Biosciences, Inc.: Upon consummation of the Reorganization, Senti Holdings adopted an Amended and Restated Certificate of Incorporation, and Senti Biosciences adopted a Third Amended and Restated Charter to simplify its certificate of incorporation after becoming a wholly-owned subsidiary (effective 2026-04-24).

Upon consummation of the Reorganization, the Amended and Restated Certificate of Incorporation of Senti Biosciences Holdings (the “Amended and Restated Certificate of Incorporation”) and the Amended and Restated Bylaws of Senti Biosciences Holdings (the “Amended and Restated Bylaws”) are the same as the second amended and restated certificate of incorporation and amended and restated bylaws of Senti Biosciences in effect immediately prior to consummation of the Reorganization, respectively, other than changes permitted by Section 251(g) of the DGCL.

SEC 8-K Item 5.03/5.05/5.06 confidence 0.4 SEC evidence

0d7194a187e7c8d95ac91d172d32d8f9db05e4f3

Senti Biosciences, Inc. amended A&R Celadon Designation Agreement with Celadon Partners SPV 24 (effective 2026-04-24).

Senti Biosciences amended and restated that certain Designation Agreement (the “Celadon Designation Agreement”) by and between Senti Biosciences and Celadon Partners SPV 24 (“Celadon”), dated December 2, 2024 (as amended and restated, the “A&R Celadon Designation Agreement”)

SEC 8-K Item 1.01/1.02 confidence 0.9 SEC evidence

3a20df659cc2902b1fec40a99ce4601c0e9a7278

Senti Biosciences, Inc. entered into Assignment and Assumption Agreement with Senti Biosciences Holdings (effective 2026-04-24).

on April 24, 2026, Senti Biosciences and Senti Biosciences Holdings entered into an Assignment and Assumption Agreement

SEC 8-K Item 1.01/1.02 confidence 0.9 SEC evidence

440b8c8c97ff307545907270431e564cc5cbd50a

Senti Biosciences, Inc. entered into Agreement and Plan of Merger with Merger Sub (effective 2026-04-24).

On April 24, 2026, Senti Biosciences completed the Reorganization by implementing the Merger pursuant to the terms of the Merger Agreement.

SEC 8-K Item 1.01/1.02 confidence 0.9 SEC evidence

9794f1412bac12e1db829009d3a4dad8a5364233

Senti Biosciences, Inc. amended A&R New Enterprise Designation Agreement with New Enterprise Associates 15, L.P. (effective 2026-04-24).

Senti Biosciences amended and restated that certain Designation Agreement by and between Senti Biosciences and New Enterprise Associates 15, L.P. (“New Enterprise”), dated December 2, 2024 (as amended and restated, the “A&R New Enterprise Designation Agreement”)

SEC 8-K Item 1.01/1.02 confidence 0.9 SEC evidence

Comparable filings

MAN

ManpowerGroup declares $0.72 dividend; shareholders approve equity plan amendment and director removal without cause

ManpowerGroup Inc. May 8, 2026, 7:59 PM ET other_material Items 5.02, 5.03, 5.07, 8.01, 9.01

same fact type: governance_change same SEC item: 5.02, 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

Senti Biosciences also amended and restated its bylaws (as so amended and restated, the “Amended and Restated Senti Biosciences Bylaws”) in order to simplify its bylaws in light of Senti Biosciences having become a wholly-owned subsidiary of Senti Holdings, which is a wholly owned subsidiary of Senti Biosciences Holdings.

Comparable filing

the Board of Directors of the Company amended Section 3.3 of Article III of the Company’s Amended and Restated By-Laws (the “ By-Laws Amendment ”) to permit the removal of a director with or without cause by the affirmative vote of two-thirds of the outstanding shares of capital stock of the Company entitled to vote at a meeting of shareholders duly called for such purpose. The effective date of the By-Laws Amendment is May 8, 2026.

Filing page SEC filing

BRANDYWINE OPERATING PARTNERSHIP, L.P.

Brandywine extends revolver maturity to Dec 2026; shareholders OK 5M share increase for LTIP

BRANDYWINE OPERATING PARTNERSHIP, L.P. June 1, 2026, 4:30 PM ET other_material Items 1.01, 2.03, 5.02, 5.07, 9.01

same fact type: material_agreement same SEC item: 1.01, 5.02, 9.01 same event type: other_material similar materiality

This filing

Senti Biosciences amended and restated that certain Designation Agreement (the “Celadon Designation Agreement”) by and between Senti Biosciences and Celadon Partners SPV 24 (“Celadon”), dated December 2, 2024 (as amended and restated, the “A&R Celadon Designation Agreement”)

Comparable filing

extended the maturity date of the Borrowers’ revolving credit facility

Filing page SEC filing

ENB

Enbridge shareholders approve directors, auditor, say-on-pay, and rights plan at AGM

ENBRIDGE INC May 7, 2026, 7:59 PM ET other_material Items 1.01, 3.03, 5.07, 9.01

same fact type: material_agreement same SEC item: 1.01, 3.03, 9.01 same event type: other_material similar materiality

This filing

Senti Biosciences amended and restated that certain Designation Agreement (the “Celadon Designation Agreement”) by and between Senti Biosciences and Celadon Partners SPV 24 (“Celadon”), dated December 2, 2024 (as amended and restated, the “A&R Celadon Designation Agreement”)

Comparable filing

the holders of common shares of Enbridge Inc. (the “Corporation”) voted to amend, reconfirm and approve the Corporation’s shareholder rights plan (the “Rights Plan”) under the terms of an agreement between the Corporation and Computershare Trust Company of Canada (“Computershare”), as rights agent.

Filing page SEC filing

WORLDS INC

Worlds Inc. changes name to Gemaxel Inc., effective March 26, 2026

WORLDS INC June 1, 2026, 2:59 PM ET other_material Items 5.03, 9.01

same fact type: governance_change same SEC item: 5.03, 9.01 same event type: other_material similar materiality

This filing

Senti Biosciences also amended and restated its bylaws (as so amended and restated, the “Amended and Restated Senti Biosciences Bylaws”) in order to simplify its bylaws in light of Senti Biosciences having become a wholly-owned subsidiary of Senti Holdings, which is a wholly owned subsidiary of Senti Biosciences Holdings.

Comparable filing

On March 26, 2026 the Company amended ARTICLE FIRST of its Certificate of Incorporation and changed its name to Gemaxel Inc. from Worlds Inc.

Filing page SEC filing

BMO 2026-5C14 Mortgage Trust

BMO 2026-5C14 transfers Compass Storage Whole Loan servicing to Benchmark 2026-V22

BMO 2026-5C14 Mortgage Trust June 1, 2026, 2:53 PM ET other_material Items 1.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 9.01 same event type: other_material similar materiality

This filing

Senti Biosciences amended and restated that certain Designation Agreement (the “Celadon Designation Agreement”) by and between Senti Biosciences and Celadon Partners SPV 24 (“Celadon”), dated December 2, 2024 (as amended and restated, the “A&R Celadon Designation Agreement”)

Comparable filing

On March 25, 2026 (the “ Closing Date ”), BMO 2026-5C14 Mortgage Trust (the “ Issuing Entity ”) issued the BMO 2026-5C14 Mortgage Trust, Commercial Mortgage Pass-Through Certificates, Series 2026-5C14, pursuant to a Pooling and Servicing Agreement, dated as of March 1, 2026 (the “ Pooling and Servicing Agreement ”), between BMO Commercial Mortgage Securities LLC, as depositor, Midland Loan Services, a Division of PNC Bank, National Association, as master servicer, CWCapital Asset Management LLC, as special servicer, Pentalpha Surveillance LLC, as operating advisor and as asset representations reviewer, and Computershare Trust Company, National Association, as certificate administrator and as trustee.

Filing page SEC filing

BTCS

BTCS reduces stockholder quorum requirement from majority to 33.3%

BTCS Inc. June 1, 2026, 9:29 AM ET other_material Items 5.03, 9.01

same fact type: governance_change same SEC item: 5.03, 9.01 same event type: other_material similar materiality

This filing

Senti Biosciences also amended and restated its bylaws (as so amended and restated, the “Amended and Restated Senti Biosciences Bylaws”) in order to simplify its bylaws in light of Senti Biosciences having become a wholly-owned subsidiary of Senti Holdings, which is a wholly owned subsidiary of Senti Biosciences Holdings.

Comparable filing

On May 29, 2026, the board of directors of BTCS Inc. (the “Company”) approved an amendment to the Company’s Amended and Restated Bylaws (the “Bylaws”) and adopted an amendment to the quorum requirement contained in Article II, Section 2.9 of the Bylaws (the “Amendment”) to provide that the holders of thirty-three and one third percent (33.3%) of the voting power of the Company entitled to vote at a meeting of stockholders, present in person or represented by proxy, shall constitute a quorum for the transaction of business.

Filing page SEC filing

MRNA

Moderna amends bylaws for federal forum exclusivity; stockholders re-elect directors

Moderna, Inc. May 11, 2026, 7:59 PM ET other_material Items 5.03, 5.07, 9.01

same fact type: governance_change same SEC item: 5.03, 9.01 same event type: other_material similar materiality

This filing

Senti Biosciences also amended and restated its bylaws (as so amended and restated, the “Amended and Restated Senti Biosciences Bylaws”) in order to simplify its bylaws in light of Senti Biosciences having become a wholly-owned subsidiary of Senti Holdings, which is a wholly owned subsidiary of Senti Biosciences Holdings.

Comparable filing

On May 6, 2026 , the Board of Directors (the “Board”) of Moderna, Inc. (the “Company”) approved an amendment to the Company’s Second Amended and Restated By-Laws (the “By-Law Amendment”), effective immediately, to designate the federal district courts of the United States as the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, unless the Company consents in writing to the selection of an alternative forum.

Filing page SEC filing

LKQ

LKQ stockholders approve 25% special meeting right; all director nominees elected

LKQ CORP May 8, 2026, 7:59 PM ET other_material Items 5.03, 5.07, 9.01

same fact type: governance_change same SEC item: 5.03, 9.01 same event type: other_material similar materiality

This filing

Senti Biosciences also amended and restated its bylaws (as so amended and restated, the “Amended and Restated Senti Biosciences Bylaws”) in order to simplify its bylaws in light of Senti Biosciences having become a wholly-owned subsidiary of Senti Holdings, which is a wholly owned subsidiary of Senti Biosciences Holdings.

Comparable filing

the Company’s stockholders, upon the recommendation of the Company’s board of directors (the “Board”), approved an amendment (the “Charter Amendment”) to the Company’s Restated Certificate of Incorporation to provide stockholders holding a combined 25% or more of the Company’s common stock with the right to request a special meeting of stockholders.

Filing page SEC filing

Source: SEC EDGAR

accession 0001193125-26-177157

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.